Replimune soars on plans to resubmit melanoma drug application

Bristol-Myers Squibb Co

29/05/2026 13:16

** Shares of Replimune REPL.O zooms 73.5% to $8.12 premarket
** The biotech firm said it would resubmit application for its experimental treatment for advanced skin cancer, after reaching an agreement with the U.S. FDA
** The treatment, RP1, also known as vusolimogene oderparepvec, is being tested with Bristol Myers Squibb's BMY.N Opdivo for patients whose advanced melanoma has worsened after prior treatment
** FDA had twice rejected the drug, citing issues in clinical trials and inadequate evidence of effectiveness
** REPL says it would resubmit the application in the coming days and FDA would treat the resubmission as an urgent matter
** As of last close, REPL down 51.9% YTD 

 (Reporting by Kunal Das in Bengaluru)
 ((Kunal.Das2@thomsonreuters.com;))